Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.70 |
| ▸ | PPARA | Q07869 | 2/20 | 0.66 |
| ▸ | PPARG | P37231 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | CDC25B | P30305 | 1/20 | 0.60 |
| ▸ | CASP6 | P55212 | 1/20 | 0.60 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.60 |
| ▸ | RARB | P10826 | 8/20 | 0.56 |
| ▸ | RARA | P10276 | 2/20 | 0.56 |
| ▸ | RARG | P13631 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PLK1 | P53350 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10801712 | 1.00 | KAT8 (0.70) | KAT8PPARAPPARGALDH1A1CDC25B | |
| SCHEMBL10364256 | 0.94 | ALDH1A1 (0.64) | KAT8PPARAPPARGALDH1A1CDC25B | |
| SCHEMBL27568950 | 0.88 | PPARA (0.70) | KAT8PPARAPPARGALDH1A1RARB | |
| SCHEMBL2075723 | 0.88 | PPARA (0.70) | KAT8PPARAPPARGALDH1A1RARB | |
| SCHEMBL7018271 | 0.87 | ALDH1A1 (0.68) | KAT8PPARAPPARGALDH1A1CDC25B | |
| SCHEMBL4474816 | 0.86 | PPARA (0.68) | KAT8PPARAPPARGALDH1A1RARB | |
| SCHEMBL8672001 | 0.85 | KAT8 (0.56) | KAT8PPARAPPARGALDH1A1CDC25B | |
| SCHEMBL10792437 | 0.85 | KAT8 (0.77) | KAT8PPARAPPARGALDH1A1RARB | |
| SCHEMBL3029363 | 0.85 | KAT8 (0.77) | KAT8PPARAPPARGALDH1A1RARB | |
| SCHEMBL3033031 | 0.85 | KAT8 (0.77) | KAT8PPARAPPARGALDH1A1RARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877750-B2 | 2-oxy-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2014-11-04 | — | — | US | disclosed |
| US-8877750-B2 | 2-oxy-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2014-11-04 | — | — | US | disclosed |
| US-8877750-B2 | 2-oxy-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2014-11-04 | — | — | US | disclosed |
| EP-1143977-B3 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | NORGINE BV (NL) | 2012-10-24 | — | — | EP | disclosed |
| EP-1143977-B3 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | NORGINE BV (NL) | 2012-10-24 | — | — | EP | disclosed |
| US-20110065697-A1 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | NORGINE B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| US-20110065697-A1 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | NORGINE B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| US-20110065697-A1 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | NORGINE B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| US-7858617-B2 | 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one; inhibition of a lipase, esterase or phosphatase enzyme | NORGINE B.V. (NL) | 2010-12-28 | — | — | US | disclosed |
| US-7858617-B2 | 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one; inhibition of a lipase, esterase or phosphatase enzyme | NORGINE B.V. (NL) | 2010-12-28 | — | — | US | disclosed |
| US-20080161301-A1 | 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one; inhibition of a lipase, esterase or phosphatase enzyme | ALIZYME THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | US | disclosed |
| US-20080161301-A1 | 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one; inhibition of a lipase, esterase or phosphatase enzyme | ALIZYME THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | US | disclosed |
| EP-1143977-B1 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | ALIZYME THERAPEUTICS LTD (GB) | 2005-04-20 | — | — | EP | disclosed |
| US-20030195206-A1 | An enzyme inhibitors, enzyme is to catalyse the hydrolysis of an ester; treating hyperlipaemia, hyperglycaemia (type II diabetes), hypertension, cardiovascular disorders stroke, gastrointestinal disease; chemical intermediate synthesis | NORGINE B.V. (NL) | 2003-10-16 | — | — | US | disclosed |
| US-6624161-B2 | Administering 2-oxy substituted benzoxazin-5-one derivative to a human or animal for the prevention or treatment of obesity or an obesity related disorder | ALIZYME THERAPEUTICS LIMITED (GB) | 2003-09-23 | — | — | US | disclosed |
| US-20030027821-A1 | Administering 2-oxy substituted benzoxazin-5-one derivative to a human or animal for the prevention or treatment of obesity or an obesity related disorder | NORGINE B.V. (NL) | 2003-02-06 | — | — | US | disclosed |
| WO-2000040247-A9 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | ALIZYME THERAPEUTICS LTD (GB) | 2002-10-24 | — | — | WO | disclosed |
| CN-1359378-A | 2-oxo-4H-3, 1-benzoxazine 4-ones for the treatment of obesity | ALIZYME THERAPEUTICS LTD (GB) | 2002-07-17 | — | — | CN | disclosed |
| EP-1144395-A1 | 2-AMINO-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | Alizyme Therapeutics Limited (GB) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000040569-A1 | 2-AMINO-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | ALIZYME THERAPEUTICS LIMITED (GB) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161301-A1 | 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one; inhibition of a lipase, esterase or phosphatase enzyme | LPL, LIPE, PNLIP | KAT8 1792/4885PPARA 570/4885PPARG 567/4885 |
| US-20110065697-A1 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | CYP1B1, CYP4X1, ACOX1 | KAT8 1524/4885PPARA 469/4885PPARG 188/4885 |
| US-20030027821-A1 | Administering 2-oxy substituted benzoxazin-5-one derivative to a human or animal for the prevention or treatment of obesity or an obesity related disorder | CYP2F1, BBOX1, CES1 | KAT8 1593/4885PPARA 451/4885PPARG 217/4885 |
| US-20030195206-A1 | An enzyme inhibitors, enzyme is to catalyse the hydrolysis of an ester; treating hyperlipaemia, hyperglycaemia (type II diabetes), hypertension, cardiovascular disorders stroke, gastrointestinal disease; chemical intermediate synthesis | CES1, LIPC, PNLIP | KAT8 1137/4885PPARA 2025/4885PPARG 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.